101 related articles for article (PubMed ID: 3184468)
21. Chronic lymphocytic leukemia in the course of chronic myelocytic leukemia: evidence of independent clonal origin as shown by interphase fluorescence in situ hybridization and fluorescence-activated cell sorting.
Chang H; Sutherland R; Nayar R; Li D; Kamel-Reid S; Mile MA; Messner H; Lipton J
Cancer Genet Cytogenet; 2004 Jul; 152(2):146-8. PubMed ID: 15262435
[TBL] [Abstract][Full Text] [Related]
22. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Cortes J; Kantarjian H
Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
[TBL] [Abstract][Full Text] [Related]
23. Presence of t(1;14)(p13;p11.2) in Philadelphia chromosome-negative cells in a patient with chronic myeloid leukemia.
Medeiros BC; Markovic V; Kamel-Reid S; Lipton JH
Cancer Genet Cytogenet; 2007 Feb; 173(1):83-4. PubMed ID: 17284377
[No Abstract] [Full Text] [Related]
24. Atypical chronic myeloid leukemias.
Oscier D
Pathol Biol (Paris); 1997 Sep; 45(7):587-93. PubMed ID: 9404484
[TBL] [Abstract][Full Text] [Related]
25. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
26. Translocation T(4;21) associated with the Pelger-Hüet anomaly in a patient with Ph chromosome-negative CML.
Yermiahu T; Dvilansky A; Manor E
Am J Hematol; 1996 Aug; 52(4):328-9. PubMed ID: 8701957
[No Abstract] [Full Text] [Related]
27. Karyotype analysis in chronic myelogenous leukemia. A three-year experience at the American University of Beirut Medical Center (AUBMC).
el-Assaad W; al-Oreibi G; Zahed L
J Med Liban; 1998; 46(1):16-9. PubMed ID: 9795517
[TBL] [Abstract][Full Text] [Related]
28. Chronic myeloproliferative disorders--introduction.
Skoda R; Prchal JT
Semin Hematol; 2005 Oct; 42(4):181-3. PubMed ID: 16210031
[No Abstract] [Full Text] [Related]
29. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
[TBL] [Abstract][Full Text] [Related]
30. Chronic myeloproliferative disorder with t(8;22)(p11;q11) can mime clonal cytogenetic evolution of authentic chronic myelogeneous leukemia.
Richebourg S; Theisen O; Plantier I; Parry A; Soenen-Cornu V; Lepelley P; Preudhomme C; Renneville A; Laï JL; Roche-Lestienne C
Genes Chromosomes Cancer; 2008 Oct; 47(10):915-8. PubMed ID: 18615682
[No Abstract] [Full Text] [Related]
31. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.
Mittal P; Saliba RM; Giralt SA; Shahjahan M; Cohen AI; Karandish S; Onida F; Beran M; Champlin RE; de Lima M
Bone Marrow Transplant; 2004 May; 33(10):1005-9. PubMed ID: 15048141
[TBL] [Abstract][Full Text] [Related]
32. A chronic myelogenous leukemia-like myeloproliferative disorder accompanied by T-cell lymphoblastic lymphoma with chromosome translocation t(8;13)(p11;q12): a Japanese case.
Matsumoto K; Morita K; Takada S; Sakura T; Shiozaki H; Murakami H; Miyawaki S
Int J Hematol; 1999 Dec; 70(4):278-82. PubMed ID: 10643154
[TBL] [Abstract][Full Text] [Related]
33. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes.
Haferlach C; Rieder H; Lillington DM; Dastugue N; Hagemeijer A; Harbott J; Stilgenbauer S; Knuutila S; Johansson B; Fonatsch C
Genes Chromosomes Cancer; 2007 May; 46(5):494-9. PubMed ID: 17311250
[TBL] [Abstract][Full Text] [Related]
34. Molecular evidence of transient complete remission after autografting in Ph-/bcr rearranged chronic myelogenous leukaemia.
Lo Coco F; Saglio G; De Fabritiis P; Diverio D; Guerrasio A; Rosso C; Meloni G; Mancini M; Mandelli F
Br J Haematol; 1989 Jun; 72(2):285-6. PubMed ID: 2667624
[No Abstract] [Full Text] [Related]
35. Current world literature.
Curr Opin Hematol; 2011 Mar; 18(2):124-31. PubMed ID: 21307671
[No Abstract] [Full Text] [Related]
36. [Application of novel tyrosine-kinase inhibitors for the treatment of leukemia and Ph-negative myeloproliferative neoplasms].
Kirito K
Rinsho Ketsueki; 2011 Jul; 52(7):460-8. PubMed ID: 21821977
[No Abstract] [Full Text] [Related]
37. Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.
Mughal TI; Radich JP; Van Etten RA; Quintás-Cardama A; Skorski T; Ravandi F; DeAngelo DJ; Gambacorti-Passerini C; Martinelli G; Tefferi A
Am J Hematol; 2011 Sep; 86(9):811-9. PubMed ID: 21850662
[TBL] [Abstract][Full Text] [Related]
38. [Chronic myeloid leukemia/chronic myeloproliferative disorders].
Ohyashiki K
Nihon Rinsho; 2007 Jan; 65 Suppl 1():250-3. PubMed ID: 17474419
[No Abstract] [Full Text] [Related]
39. A CALR mutation preceding BCR-ABL1 in an atypical myeloproliferative neoplasm.
Cabagnols X; Cayuela JM; Vainchenker W
N Engl J Med; 2015 Feb; 372(7):688-90. PubMed ID: 25671272
[No Abstract] [Full Text] [Related]
40. [New mutations in myeloproliferative neoplasms; 2014 update].
Kirito K
Rinsho Ketsueki; 2014 Oct; 55(10):1833-40. PubMed ID: 25297747
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
